Note 1 - Description of Business (Details Textual) $ / shares in Units, $ in Thousands					1 Months Ended	12 Months Ended
	Feb. 18, 2025 USD ($) $ / shares shares	Jun. 14, 2024	Apr. 12, 2024 $ / shares shares	Apr. 11, 2024 USD ($) $ / shares shares	Feb. 28, 2026 USD ($)	Dec. 31, 2025 USD ($) $ / shares	Dec. 31, 2024 USD ($) $ / shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period, shares | shares	3,379,377
Stock purchase price per share	$ 3.02
Proceeds from issuance of common stock | $	$ 10,200
Common stock, par value						$ 0.001	$ 0.001
Reverse stock split, ratio		0.1
Common stock, par value (in dollars per share)						0.001	0.001
Preferred stock, par value						$ 0.001	$ 0.001
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]						srt:ChiefExecutiveOfficerMember
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description						regularly reviews scientific data from clinical and preclinical studies and forecasted expenses for continued operations.
Effective income tax rate						0.80%	2.60%
Cash, cash equivalents and short-term investments | $						$ 144,700
Accumulated deficit | $						(334,840)	$ (231,719)
Loss on equity method investment | $						$ 2	$ 8
GT Medical Technologies, Inc. [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period, shares | shares			279,516
Common stock, par value			$ 0.0001
Common stock, par value (in dollars per share)			$ 0.0001
Percentage of issued and outstanding capital stock			0.50%
Oppenheimer & Co [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued during period, shares | shares				3,535,246
Stock purchase price per share				$ 14
Proceeds from issuance of common stock | $				$ 49,500
Subsequent Event [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Gross proceeds from closing of underwritten offering | $					$ 175,000